Information  X 
Enter a valid email address

Company Name matching 'INVENTIVA'

Date
Time Source
Company
Announcement
20 Jan 2022 9:00 pm GNW   INVENTIVA Inventiva announces participation at several conferences in January and February 2022
16 Dec 2021 9:00 pm GNW   INVENTIVA Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference
06 Dec 2021 9:00 pm GNW   INVENTIVA Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
10 Nov 2021 9:00 pm GNW   INVENTIVA Inventiva reports 2021 Third Quarter Financial Information
03 Nov 2021 8:00 pm GNW   INVENTIVA Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021  
29 Oct 2021 2:29 pm GNW   INVENTIVA Inventiva announces participation at several conferences in November 2021
27 Oct 2021 9:00 pm GNW   INVENTIVA Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes
20 Oct 2021 10:07 pm GNW   INVENTIVA The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
18 Oct 2021 9:00 pm GNW   INVENTIVA Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
28 Sep 2021 9:00 pm GNW   INVENTIVA Inventiva announces participation at several investor conferences in October 2021
23 Sep 2021 7:45 am GNW   INVENTIVA Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors
21 Sep 2021 9:00 pm GNW   INVENTIVA Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis
20 Sep 2021 9:10 pm GNW   INVENTIVA Inventiva reports 2021 first half financial results and provides a corporate update
16 Sep 2021 9:00 pm GNW   INVENTIVA Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH
10 Sep 2021 2:00 pm GNW   INVENTIVA Inventiva’s 2021 First-Half Financial Results Presentation
08 Sep 2021 9:00 pm GNW   INVENTIVA Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
30 Aug 2021 9:00 pm GNW   INVENTIVA Inventiva announces participation at several investor conferences in September 2021  
02 Aug 2021 10:00 pm GNW   INVENTIVA Inventiva announces the implementation of an At-The-Market program in the United States
28 Jul 2021 9:00 pm GNW   INVENTIVA Inventiva Reports First-Half of 2021 Financial Information
15 Jun 2021 9:00 pm GNW   INVENTIVA Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day
09 Jun 2021 9:00 pm GNW   INVENTIVA Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast event
25 May 2021 9:00 pm GNW   INVENTIVA Inventiva to participate at the Jefferies Virtual Healthcare Conference
12 May 2021 9:00 pm GNW   INVENTIVA Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases
26 Apr 2021 9:00 pm GNW   INVENTIVA Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit
19 Apr 2021 9:00 pm GNW   INVENTIVA Appointment of Martine Zimmermann as Independent Director to Inventiva’s Board of Directors
04 Mar 2021 9:00 pm GNW Factsheet INVENTIVA (0RNK) 2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States
25 Feb 2021 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvemen
24 Feb 2021 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva to participate at several investor conferences in March 2021
11 Feb 2021 9:00 pm GNW Factsheet INVENTIVA (0RNK) Full-Year 2020: Cash position and revenues
06 Jan 2021 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva annonce sa participation à la « 39th Annual J.P. Morgan Healthcare Conference »
05 Jan 2021 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva announces design of Phase III clinical trial with lanifibranor in NASH
07 Dec 2020 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis
24 Nov 2020 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
12 Nov 2020 9:00 pm GNW Factsheet INVENTIVA (0RNK) Q3 2020 Financial Information
10 Nov 2020 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva receives positive FDA feedback to advance its lead drug candidate lanifibranor into pivotal Phase III in NASH
09 Nov 2020 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva to participate at the Stifel Virtual Healthcare Conference 2020 and the 11th Jefferies Virtual Healthcare Conference
05 Nov 2020 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva announces the appointment of Dr. Michael Cooreman as Chief Medical Officer
02 Nov 2020 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva announces the publication of a scientific paper on the role of PPARs in the treatment of NASH in the medical journal Nature Review Gastroenterology & Hepatology
  7:00 am GNW Factsheet INVENTIVA (0RNK) Inventiva announces the additional acceptance of two late-breaking abstracts at the AASLD The Liver Meeting Digital Experience™ 2020
28 Oct 2020 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva to host a Key Opinion Leader webcast from the AASLD The Liver Meeting Digital Experience™ 2020
19 Oct 2020 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci
12 Oct 2020 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH
05 Oct 2020 9:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva selected to present the results of its NATIVE Phase IIb clinical trial with lanifibranor in NASH during a plenary session at The Liver Meeting Digital Experience™ 2020
24 Sep 2020 5:15 pm GNW Factsheet INVENTIVA (0RNK) Inventiva to participate at several investor conferences in October 2020
16 Sep 2020 9:00 pm GNW Factsheet INVENTIVA (0RNK) H1 2020 financial results and corporate business update
09 Sep 2020 4:45 pm GNW Factsheet INVENTIVA (0RNK) Inventiva to participate at several investor conferences in September 2020
06 Jul 2020 5:30 pm GNW Factsheet INVENTIVA (0RNK) H1 2020 Financial Information
  7:00 am GNW Factsheet INVENTIVA (0RNK) Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)
15 Jun 2020 5:20 pm GNW Factsheet INVENTIVA (0RNK) Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH
02 Jun 2020 4:45 pm GNW Factsheet INVENTIVA (0RNK) Inventiva to participate at the Jefferies Virtual Healthcare Conference
25 May 2020 4:45 pm GNW Factsheet INVENTIVA (0RNK) Inventiva secures a new patent for lanifibranor in China expanding the protection of its lead product candidate
19 May 2020 4:45 pm GNW Factsheet INVENTIVA (0RNK) Inventiva secures €10.0 m non-dilutive loan facility guaranteed by the French State in the context of the COVID-19 pandemic
18 May 2020 4:45 pm GNW Factsheet INVENTIVA (0RNK) Inventiva’s latest research on odiparcil’s mechanism of action published in leading peer-reviewed scientific journal PLOS ONE
14 May 2020 4:45 pm GNW Factsheet INVENTIVA (0RNK) Q1 2020 Financial Information
21 Apr 2020 4:45 pm GNW Factsheet INVENTIVA (0RNK) Inventiva to provide an update on the NATIVE Phase IIb clinical trial in NASH during a Key Opinion Leader webcast
07 Apr 2020 5:00 pm GNW Factsheet INVENTIVA (0RNK) Inventiva provides a corporate business update in the context of the COVID-19 pandemic
17 Mar 2020 4:45 pm GNW Factsheet INVENTIVA (0RNK) Inventiva announces completion of patient visits for its Phase IIb clinical study with lanifibranor in NASH
10 Mar 2020 4:45 pm GNW Factsheet INVENTIVA (0RNK) 2019 Full-Year Results: Significant progress in NASH, MPS VI and psoriasis, and extended cash runway
19 Feb 2020 4:45 pm GNW Factsheet INVENTIVA (0RNK) Inventiva to present at the Cowen and Company 40th Annual Health Care Conference
07 Feb 2020 7:00 am GNW Factsheet INVENTIVA (0RNK) Inventiva completes a capital increase of €15 m subscribed by existing shareholders


Company Announcements Archive »


a d v e r t i s e m e n t